Menu
Post-Trial Access (PTA) is more than an ethical obligation—it’s a strategic opportunity to demonstrate patient commitment, extend treatment benefit, and
Currently there are 6,000 recognised rare diseases, affecting over 300 million people globally. Despite these staggering numbers, only 5% of
Clinical trials are by design, a scientific experiment, which require highly selective populations in a controlled setting, and with often
Real-world evidence (RWE) is increasingly being used within the regulatory and reimbursement process. RWE studies allow for a clearer understanding
Background The pharmaceutical manufacturer (Sponsor) aimed to study the real-world effectiveness and usage of their medicine in patients with
Background The pharmaceutical manufacturer (Sponsor) wanted to understand the effectiveness of their medication in the real-world. For this
Recorded: 15th May 2024 This webinar is aimed at Pharma and Biotech professionals who work on rare disease drug development
Cisiv, a leading provider of innovative technology solutions in the life sciences industry, has announced the appointment of Dr Romina
To find out more about the Cisiv technology and how we can help you with your study.